	US 12,213,963 B2
	Topical formulation of disease-modifying antirheumatic drug (DMARDs) for the treatment of rheumatoid arthritis, melanoma, squamous cell carcinoma, atopic dermatitis, and psoriasis
Manoj Purushottam Jadhav, Hillsborough, NJ (US); Mangal Shailesh Nagarsenkar, Thane (IN); Supriya Shrihari Shidhaye, Mumbai (IN); Shivali Hargovind Tank, Mumbain (IN); Bhagyashri Surendra Parab, Mumbai (IN); Pradnya Nikhil Korlekar, Mumbai (IN); Anita Pandurang Ayre, Mumbai (IN); and Palak Karia, Mumbai (IN)
Assigned to Manoj Jadhav, Hillsborough, NJ (US)
Filed by Manoj Purushottam Jadhav, Hillsborough, NJ (US)
Filed on Oct. 19, 2022, as Appl. No. 18/047,707.
Prior Publication US 2024/0131008 A1, Apr. 25, 2024 Prior Publication US 2024/0226068 A9, Jul. 11, 2024
Int. Cl. A61K 31/42 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/44 (2017.01)

CPC A61K 31/42 (2013.01) [A61K 9/0014 (2013.01); A61K 9/1075 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01)]

4 Claims

1. A topical microemulsion-based emulgel composition comprising:

a. 0.5-1.0 (% w/v) leflunomide;

b. 5 (% w/v) propylene glycol monocaprylate;

c. 3.75 (% w/v) polysorbate 20;

d. 3.75 (% w/v) polyoxyl 40 hydrogenated castor oil;

e. 7.5 (% w/v) polyethylene glycol 400;

f. 2.5 (% w/v) carbomer; and

g. q.s. water.